Literature DB >> 8345214

Identification of a mammalian melanosomal matrix glycoprotein.

S J Orlow1, B K Zhou, R E Boissy, S Pifko-Hirst.   

Abstract

Antiserum raised in rabbits against the Triton X-100 insoluble fraction of melanosomes from mouse melanoma cells specifically decorates the internal matrix of melanosomes in immunoelectron microscopy. In metabolic labeling studies, the antiserum recognizes a protein of 94 kDa, which is processed to a band of 53 kDa. Whereas the precursor is relatively soluble in buffers containing Triton X-100, the processed protein requires the addition of sodium dodecyl sulfate for effective solubilization, as would be expected for a melanosomal matrix constituent. Tunicamycin reduces the Mr of the nascent protein to 75 kDa, but deoxymannojirimycin and swainsonine have no effect, suggesting that following initial glycosylation in the endoplasmic reticulum, the protein is not subject to processing by glycosidases in the Golgi apparatus or may bypass it entirely. Subcellular fractionation followed by immunoblotting confirms that the protein is present in the melanosome-rich, large granule fraction. Expression of the protein is regulated differently from that of the tyrosinase-related protein family. Conditions that greatly stimulate expression of tyrosinase-related proteins do not affect matrix protein expression, nor is the protein immunologically related to the tyrosinase-related protein family. Our results suggest that we have identified an authentic component of the mammalian melanosomal matrix, and that its characteristics lend support to a bipartite pathway for melanosomal biogenesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8345214     DOI: 10.1111/1523-1747.ep12363626

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

1.  A novel splice variant of Pmel17 expressed by human melanocytes and melanoma cells lacking some of the internal repeats.

Authors:  Sarah E Nichols; Dawn C Harper; Joanne F Berson; Michael S Marks
Journal:  J Invest Dermatol       Date:  2003-10       Impact factor: 8.551

Review 2.  PMEL: a pigment cell-specific model for functional amyloid formation.

Authors:  Brenda Watt; Guillaume van Niel; Graça Raposo; Michael S Marks
Journal:  Pigment Cell Melanoma Res       Date:  2013-02-19       Impact factor: 4.693

3.  The PKD domain distinguishes the trafficking and amyloidogenic properties of the pigment cell protein PMEL and its homologue GPNMB.

Authors:  Alexander C Theos; Brenda Watt; Dawn C Harper; Karolina J Janczura; Sarah C Theos; Kathryn E Herman; Michael S Marks
Journal:  Pigment Cell Melanoma Res       Date:  2013-04-02       Impact factor: 4.693

Review 4.  The Silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function.

Authors:  Alexander C Theos; Steven T Truschel; Graça Raposo; Michael S Marks
Journal:  Pigment Cell Res       Date:  2005-10

5.  Identification of a melanosomal matrix protein encoded by the murine si (silver) locus using "organelle scanning".

Authors:  B K Zhou; T Kobayashi; P D Donatien; D C Bennett; V J Hearing; S J Orlow
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

6.  The ocular albinism type 1 gene product is a membrane glycoprotein localized to melanosomes.

Authors:  M V Schiaffino; C Baschirotto; G Pellegrini; S Montalti; C Tacchetti; M De Luca; A Ballabio
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

Review 7.  PMEL Amyloid Fibril Formation: The Bright Steps of Pigmentation.

Authors:  Christin Bissig; Leila Rochin; Guillaume van Niel
Journal:  Int J Mol Sci       Date:  2016-08-31       Impact factor: 5.923

8.  Proprotein convertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate melanosome biogenesis.

Authors:  Joanne F Berson; Alexander C Theos; Dawn C Harper; Danielle Tenza; Graça Raposo; Michael S Marks
Journal:  J Cell Biol       Date:  2003-05-05       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.